XML 32 R19.htm IDEA: XBRL DOCUMENT v3.23.3
BUSINESS SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
BUSINESS SEGMENT INFORMATION BUSINESS SEGMENT INFORMATION
    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, customers, and ACOs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95% of net revenues in 2023 and 2022.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
        
    As of September 30, 2023, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

    The following table is a summary of segment information for the three and nine months ended September 30, 2023 and 2022. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2022 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net revenues:    
DIS business$2,228 $2,419 $6,755 $7,344 
All other operating segments67 67 209 206 
Total net revenues $2,295 $2,486 $6,964 $7,550 
Operating earnings (loss):    
DIS business$392 $441 $1,176 $1,445 
All other operating segments8 3 26 16 
General corporate activities(58)(52)(207)(168)
Total operating income342 392 995 1,293 
Non-operating expense, net(43)(41)(102)(167)
Income before income taxes and equity in earnings of equity method investees299 351 893 1,126 
Income tax expense(68)(81)(208)(268)
Equity in earnings of equity method investees, net of taxes6 6 18 41 
Net income237 276 703 899 
Less: Net income attributable to noncontrolling interests12 20 41 54 
Net income attributable to Quest Diagnostics$225 $256 $662 $845 

    The approximate percentage of net revenues by major service for the three and nine months ended September 30, 2023 and 2022 were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Routine clinical testing and other services51 %45 %50 %43 %
COVID-19 testing services1 13 3 17 
Gene-based and esoteric (including advanced diagnostics) testing services39 33 38 31 
Anatomic pathology testing services6 6 6 6 
All other3 3 3 3 
Net revenues100 %100 %100 %100 %